Catalyst Wire Dossier Catalyst Wire Dossier

CGB-500 topical ointment

tofacitinib · CAGE Bio Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CGB-500 topical ointment, covering 2026-04-02 to 2026-04-02. Get the full timeline:

Most recent: Clinical Trial Update: Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis [Phase 2]

See pricing